IPV Vaccines Market, by Vaccine Brand (POLIOVAC (PFS/SD), SHANIPV, POLIORIX, IPOL/IMOVAX, And POLYMILEX), by Distribution Channel (Private and Public), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

Published In : Mar 2024

Code : CMI4965

Pages :220

Formats :

Excel and PDF

Industry : Biotechnology

Market Challenges And Opportunities

Global IPV Vaccines Market - Restraint

Inactivated polio vaccines are given to millions of children and adults for the prevention of polio. Although, in some cases, this immunization shows side effects including: rash, itching.

According to several research studies, immunization with inactivated polio vaccines are less effective. For instance, inactivated polio vaccines (IPV) weaken immunity in the intestine. Moreover, after immunization with IPV, every person gets infected with wild poliovirus, which multiply in the intestines.

Therefore, these side effects can pose major challenges such as decreasing community acceptance for such inactivated polio vaccines, which in turn is expected to hamper growth of Global Inactivated Polio Vaccines Market.

High cost of inactivated polio vaccines in comparison with oral polio vaccines may negatively impact growth of the inactivated polio vaccines market.

For instance, in 2019, according to the World Health Organization, the weighted average price of IPV vaccines per dose is US$ 2.8 while the price per dose of OPV vaccine ranges from US$ 0.12 to 0.17 in PAHO countries.

Restraints & Challenges:

Side effects associated with immunization and high cost of inactivated polio vaccines
Introduction of combination vaccines

In December 2022, Sudan's Federal Ministry of Health, in collaboration with the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), initiated a catch-up vaccination program to immunize children against polio and yellow fever from December 29, 2022 to January 3, 2023.

In June 2020, Batavia Biosciences, a CDMO for Viral Vectors and Viral Vaccines, and Valneva Sweden AB, a Sweden-based subsidiary of Valneva SE, a specialty vaccine company announced that they have entered into a collaboration agreement to speed market access for a low-cost inactivated polio vaccine (IPV). According to the terms of the collaboration, Valneva SEwill use Batavia Biosciences’ technique to manufacture the Sabin vaccine strains (sIPV) vaccine for clinical trials at its cutting-edge GMP polio production facility in Solna, Sweden, which is run under GAPIII polio containment.